InterMune, Inc.

Enrollment complete for phase III trial of Actimmune plus standard therapy

Published in Oncology Business Week, May 16th, 2004

InterMune, Inc., (ITMN) announced that it has completed enrollment of its pivotal phase III clinical trial evaluating the safety and efficacy of Actimmune (Interferon gamma-1b) in combination with standard chemotherapy for advanced ovarian cancer.

"The completion of enrollment in this trial, 10 months ahead of schedule, is a tribute to the diligence and commitment of InterMune and the investigators and underscores the urgent need for improved treatment regimens for this disease," said David S. Alberts, MD, regents professor of medicine, pharmacology, and public health, College of Medicine, University of Arizona, and lead principal investigator for the trial.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2004-05-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry